Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CHGCY Chugai Pharmaceutical	$21.80 -0.4%	$23.26	$19.50 ▼ $31.26	$71.74B	0.64	211,477 shs	188,739 shs
SDZNY Sandoz Group	$61.47 -2.3%	$57.97	$35.61 ▼ $63.72	$27.05B	0.6	32,891 shs	12,609 shs
TAK Takeda Pharmaceutical	$15.17 +1.2%	$14.81	$12.80 ▼ $15.56	$48.25B	0.22	2.55 million shs	2.39 million shs
ZTS Zoetis	$152.76 -2.3%	$153.49	$139.70 ▼ $200.33	$67.70B	0.88	3.07 million shs	2.18 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CHGCY Chugai Pharmaceutical	0.00%	+4.89%	-10.87%	-15.90%	-12.93%
SDZNY Sandoz Group	0.00%	+0.35%	+10.35%	+23.02%	+42.87%
TAK Takeda Pharmaceutical	0.00%	-0.63%	+5.75%	+0.10%	+0.64%
ZTS Zoetis	0.00%	+0.87%	+6.14%	-8.19%	-14.74%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CHGCY Chugai Pharmaceutical	2.4152 of 5 stars	0.0	5.0	1.7	0.0	2.2	0.0	1.9
SDZNY Sandoz Group	1.3235 of 5 stars	0.0	3.0	0.8	0.0	2.4	0.0	1.9
TAK Takeda Pharmaceutical	2.5901 of 5 stars	0.0	4.0	2.5	0.0	2.7	0.0	1.9
ZTS Zoetis	4.8457 of 5 stars	3.3	4.0	4.2	0.4	3.5	2.5	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CHGCY Chugai Pharmaceutical	0.00	N/A	N/A	N/A
SDZNY Sandoz Group	2.00	Hold	N/A	N/A
TAK Takeda Pharmaceutical	2.00	Hold	N/A	N/A
ZTS Zoetis	2.50	Moderate Buy	$202.43	32.51% Upside

Current Analyst Ratings Breakdown

Latest SDZNY, CHGCY, ZTS, and TAK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2025	TAK Takeda Pharmaceutical	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/11/2025	ZTS Zoetis	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$210.00 ➝ $215.00
8/8/2025	SDZNY Sandoz Group	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/17/2025	ZTS Zoetis	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/17/2025	ZTS Zoetis	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$180.00 ➝ $155.00
6/18/2025	ZTS Zoetis	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$165.00 ➝ $160.00

(Data available from 9/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CHGCY Chugai Pharmaceutical	$7.74B	9.27	$0.84 per share	26.00	$3.81 per share	5.72
SDZNY Sandoz Group	$10.36B	2.61	$2.61 per share	23.53	$18.56 per share	3.31
TAK Takeda Pharmaceutical	$30.09B	1.60	$3.22 per share	4.71	$14.39 per share	1.05
ZTS Zoetis	$9.26B	7.31	$6.91 per share	22.12	$10.57 per share	14.45

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CHGCY Chugai Pharmaceutical	$2.56B	$0.79	27.60	27.95	N/A	33.08%	20.80%	18.17%	10/24/2025 (Estimated)
SDZNY Sandoz Group	$1M	N/A	0.00	18.52	1.06	N/A	N/A	N/A	N/A
TAK Takeda Pharmaceutical	$712.33M	$0.30	50.55	9.19	N/A	3.20%	10.50%	5.10%	10/30/2025 (Estimated)
ZTS Zoetis	$2.49B	$5.81	26.29	22.63	2.51	27.83%	56.90%	19.54%	11/3/2025 (Estimated)

Latest SDZNY, CHGCY, ZTS, and TAK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	ZTS Zoetis	$1.62	$1.76	+$0.14	$1.61	$2.41 billion	$2.46 billion
7/30/2025	Q1 2026	TAK Takeda Pharmaceutical	$0.47	$0.52	+$0.05	$0.27	$7.96 billion	$7.45 billion
7/24/2025	Q2 2025	CHGCY Chugai Pharmaceutical	N/A	$0.20	N/A	$0.20	N/A	$2.01 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CHGCY Chugai Pharmaceutical	$0.13	0.60%	N/A	16.46%	N/A
SDZNY Sandoz Group	$0.44	0.72%	N/A	N/A	N/A
TAK Takeda Pharmaceutical	$0.55	3.63%	N/A	183.33%	N/A
ZTS Zoetis	$2.00	1.31%	N/A	34.42%	14 Years

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CHGCY Chugai Pharmaceutical	N/A	6.04	5.16
SDZNY Sandoz Group	0.57	1.24	0.79
TAK Takeda Pharmaceutical	0.60	1.16	0.59
ZTS Zoetis	1.05	1.76	1.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CHGCY Chugai Pharmaceutical	0.01%
SDZNY Sandoz Group	0.06%
TAK Takeda Pharmaceutical	9.17%
ZTS Zoetis	92.80%

Insider Ownership

Company	Insider Ownership
CHGCY Chugai Pharmaceutical	N/A
SDZNY Sandoz Group	N/A
TAK Takeda Pharmaceutical	0.04%
ZTS Zoetis	0.16%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CHGCY Chugai Pharmaceutical	7,778	3.29 billion	N/A	Not Optionable
SDZNY Sandoz Group	23,406	440.00 million	N/A	Not Optionable
TAK Takeda Pharmaceutical	47,455	3.18 billion	3.18 billion	Optionable
ZTS Zoetis	13,800	443.18 million	442.47 million	Optionable

SDZNY, CHGCY, ZTS, and TAK Headlines

Recent News About These Companies

Phibro Animal Health: Zoetis Growth, Valuation Still Attractive

September 2 at 9:30 AM | seekingalpha.com

Baird Financial Group Inc. Increases Stock Position in Zoetis Inc. $ZTS

September 2 at 6:41 AM | marketbeat.com

The Manufacturers Life Insurance Company Sells 37,953 Shares of Zoetis Inc. $ZTS

September 2 at 6:05 AM | marketbeat.com

Zoetis Inc. (ZTS) Reports $2.5B Q2 Revenue, Raises Full-Year Outlook on Strong Pet Care Demand

September 2 at 3:51 AM | insidermonkey.com

Hayek Kallen Investment Management Sells 4,478 Shares of Zoetis Inc. $ZTS

September 1 at 7:27 AM | marketbeat.com

Zoetis Inc. $ZTS Position Raised by Lansing Management LP

September 1 at 6:36 AM | marketbeat.com

Canada Pension Plan Investment Board Sells 127,556 Shares of Zoetis Inc. $ZTS

September 1 at 5:36 AM | marketbeat.com

OMERS ADMINISTRATION Corp Lowers Position in Zoetis Inc. $ZTS

September 1 at 5:03 AM | marketbeat.com

Caisse DE Depot ET Placement DU Quebec Sells 209,519 Shares of Zoetis Inc. $ZTS

September 1 at 4:35 AM | marketbeat.com

Zoetis: A Solid Dividend Growth Investment For The Long Haul

September 1 at 4:31 AM | seekingalpha.com

Vident Advisory LLC Purchases 46,659 Shares of Zoetis Inc. $ZTS

August 31 at 7:36 AM | marketbeat.com

Gerber Kawasaki Wealth & Investment Management Reduces Stock Holdings in Zoetis Inc. $ZTS

August 31 at 6:00 AM | marketbeat.com

Landscape Capital Management L.L.C. Sells 1,846 Shares of Zoetis Inc. $ZTS

August 31 at 6:00 AM | marketbeat.com

Ieq Capital LLC Increases Position in Zoetis Inc. $ZTS

August 31 at 5:31 AM | marketbeat.com

Trexquant Investment LP Has $26.57 Million Holdings in Zoetis Inc. $ZTS

August 30 at 8:04 AM | marketbeat.com

Lansforsakringar Fondforvaltning AB publ Increases Stock Holdings in Zoetis Inc. $ZTS

August 30 at 7:27 AM | marketbeat.com

Zacks Research Issues Negative Estimate for Zoetis Earnings

August 30 at 6:31 AM | marketbeat.com

Zoetis Inc. $ZTS Shares Sold by Gabelli Funds LLC

August 30 at 5:43 AM | marketbeat.com

Rafferty Asset Management LLC Sells 9,695 Shares of Zoetis Inc. $ZTS

August 30 at 5:29 AM | marketbeat.com

Analysts Set Zoetis Inc. (NYSE:ZTS) PT at $202.43

August 30 at 3:05 AM | americanbankingnews.com

Brokers Set Expectations for Zoetis' Q3 Earnings (NYSE:ZTS)

August 30 at 2:45 AM | americanbankingnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SDZNY, CHGCY, ZTS, and TAK Company Descriptions

Chugai Pharmaceutical OTCMKTS:CHGCY

$21.80 -0.09 (-0.41%)

As of 04:00 PM Eastern

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.

Sandoz Group OTCMKTS:SDZNY

$61.47 -1.42 (-2.26%)

As of 03:52 PM Eastern

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland.

Takeda Pharmaceutical NYSE:TAK

$15.16 +0.18 (+1.17%)

Closing price 03:59 PM Eastern

Extended Trading

$15.10 -0.06 (-0.40%)

As of 04:59 PM Eastern

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

Zoetis NYSE:ZTS

$152.76 -3.64 (-2.33%)

Closing price 03:59 PM Eastern

Extended Trading

$152.76 -0.01 (0.00%)

As of 05:34 PM Eastern

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time